Document:

EX-10.8

 Exhibit 10.8 

Vahanna Tech Edge Acquisition I Corp. 

(the “Company”) 

Surrender of Shares 

Pursuant to sections 59(1A) and 59(1B) 

of the 
 BVI Business Companies Act
(as amended) 
 Vahanna LLC (the “Surrendering Member”) does hereby irrevocably surrender to the Company 1,437,500 Class B ordinary
shares (the “Shares”) registered in the name of the Surrendering Member in the register of members of the Company for no consideration. 

The Surrendering Member further confirms that the Shares are fully paid up shares of the Company. 

Signed by the Surrendering Member 
  

	
	 /s/ Vinode Ramgopal

	For and on behalf of
	Vahanna LLC
	Dated this 28th day of October 2021Document

                                                                                                                        Exhibit 10.1
November 23, 2021

Dear Tim,
We are pleased to confirm our offer to have you join Rapid7, Inc. as Chief Financial Officer reporting to Corey Thomas, the Chief Executive Officer, with a start date of January 3, 2022. Your principal place of employment shall be at our headquarters in Boston, Massachusetts. You will be expected to devote your full working time and efforts to the business and affairs of Rapid7 and perform duties as are normally associated with your position and such duties as are assigned to you from time to time, subject to the oversight and direction of the Chief Executive Officer. 
Your starting annual salary will be $390,000, payable bi-weekly less any applicable withholdings or taxes. Subject to you commencing your employment with us, you will also receive a sign-on bonus of $250,000 payable within 45 days after your start date, less applicable withholdings or taxes. Should you resign from Rapid7, or are terminated by Rapid7 for Cause, as defined in Rapid7’s 2015 Equity Incentive Plan, as amended (the “Equity Plan”), at any time during your first year of employment, you will be required to repay the full sign-on amount that was paid to you within 45 days of termination or resignation, as applicable. Otherwise, you agree to have such amount be offset from your salary or other monies owed to you by Rapid7, including, but not limited to, wages, bonus and severance.
In addition, you will be eligible for a bonus opportunity expressed as 70% of your annual salary. Such bonus will be payable annually, measured based on objectives mutually agreed between you and your manager from time to time, and subject to Rapid7’s Executive Incentive Bonus Plan. As a condition precedent to earning and receiving your bonus, you must remain an active employee of Rapid7 through the date the bonus is scheduled to be paid. If your employment has been terminated for any reason before such date, then you will not be entitled to any unpaid bonus even where such bonus has been notified to you.
In connection with, and subject to, the commencement of your employment with Rapid7, you will be eligible to receive a restricted stock unit award with an approximate value of $12 million, with the underlying number of shares of common stock for such award determined using a 30-calendar day average closing price prior to the date of grant, subject to approval by the Compensation Committee of our Board of Directors and the terms and conditions of the Equity Plan (or any successor equity incentive plan) and the applicable award agreement thereunder. Such award shall vest over a four-year period with 25% vesting on February 15, 2023, with quarterly vesting thereafter, subject to your continued service on such vesting date.
In addition, subject to approval by the Compensation Committee of our Board of Directors, in the event  your employment with Rapid7 ends due to your resignation for Good Reason, as defined in Rapid7’s Severance and Equity Award Vesting Acceleration Letter Agreement (the “Severance and Acceleration Agreement”) or termination of your employment by Rapid7 other than for Cause, as defined in the Equity Plan, and other than as a result of your death or disability (“Qualifying Termination”), you will be entitled to continued payment of your salary for six months following your termination of employment and payment of premiums for continued health benefits under COBRA for up to six months; provided, however, if the Qualifying Termination occurs within three months prior to or 12 months following a change in control of Rapid7, you will be entitled to: (i) continued payment of your salary for 12 months following your termination of employment, (ii) payment of premiums for continued health benefits under COBRA for up to 12 months, (iii) pro-rated portion of your target performance bonus for the year in which the termination of employment occurs, and (iv) accelerated vesting of all of your equity awards then outstanding on such date of termination of employment. Your right to receive such payments and benefits shall be governed by and subject to the terms and conditions of the Severance and Acceleration Agreement. Notwithstanding anything to the contrary in the Severance and Acceleration Agreement, Good Reason shall be deemed to exist in the event that following a change in control of Rapid7 you do not remain the Chief Financial Officer of the new or surviving entity.
As a regular employee of Rapid7, you will be eligible to participate in our standard employee benefit package (medical, dental insurance, paid-time-off, etc.) according to the terms of each respective benefit plan. Further information regarding these plans will be sent to you prior to or shortly after your start date.
Rapid7 is an “at-will” employer. That means that both employees and Rapid7 have the right to terminate employment at any time, with or without advance notice, and with or without cause. Employees also may be demoted or disciplined and the terms of their employment may be altered at any time, with or without cause, at the discretion of Rapid7. 

Your offer is contingent upon (1) successful completion of a routine background investigation and references; (2) signing of the Rapid7 Confidentiality, Assignment, and Non-Solicitation Agreement; (3) signing of the Rapid7 Release Form; and (4) signing of the Rapid7 Employee Handbook, which acknowledges all Rapid7 policies. You also must establish your identity and authorization to work as required by the Immigration Reform and Control Act of 1986 (IRCA). Under separate cover you will receive a copy of the Employment Verification Form (I-9), with instructions required by IRCA.
This letter sets forth our entire agreement and understanding regarding the terms of your employment with Rapid7 and supersedes any prior representations or agreements, whether written or oral. This letter may not be modified in any way except in a writing signed by Rapid7 and you.
If you have questions regarding any of the foregoing, please do not hesitate to contact us. If you agree to the terms and conditions of set forth in this letter, please sign this letter where indicated below.
We look forward to your favorable reply regarding the above and to working with you at Rapid7. We are  excited for you to become a part of the Rapid7 team.

Sincerely,

			
	/s/ Christina Luconi
	Christina Luconi, Chief People Officer

I agree to the terms set out in this letter.

												
	By:	/s/ Tim Adams	Date:	November 23, 2021
		Tim AdamsExhibit
10.5

 

AMENDMENT
NO. 1 TO LICENSE AGREEMENT

 

This
AMENDMENT NO. 1 TO LICENSE AGREEMENT (this “Amendment”) is dated as of November 12, 2021 (the “Amendment
Date”) by and between Fresh Grapes, LLC, a Texas limited liability company (“Company” or “We”)
and Nina Dobrev (“Licensor” or “you”). Licensor and Company are sometimes referred to collectively
herein as the “Parties” and each is sometimes referred to herein as a “Party.”

 

RECITALS

 

A. Company
and Licensor are parties to that certain License Agreement dated as of March [*], 2021, including the Basic Terms and the Standard Terms
and Conditions (the “STCs”)(collectively, the “Agreement”). Capitalized terms not otherwise defined
in this Amendment shall have the meanings assigned to them in the Agreement.

 

B. Licensor
is a member of Company and a party to that certain Limited Liability Company Agreement of Company dated March [*], 2021, as amended (the
“Operating Agreement”).

 

C. Upon
the effective date of the Agreement and Operating Agreement (the “Effective Date”), Company granted Licensor one hundred
fifty-six thousand five hundred (156,500) Class F Units, which were described on Schedule I of the Operating Agreement as having a Percentage
Interest of 11.5%.

 

D. In
order to resolve a dispute as to the number of Class F Units that Licensor was entitled to receive upon entry into the Agreement, and
to restore Licensor’s Percentage Interest of 11.5% as of the Effective Date, concurrently with the execution and delivery of this
Amendment, Nechio & Novak FV, LLC, an existing holder of outstanding Class F Units, is assigning and transferring to Licensor twenty
thousand seven hundred two (20,702) Class F Units (the “Restored Units”)

 

E. Section
15.2 of the STCs provides that the Agreement will automatically terminate in the event Licensor ceases to be a Member of Company or upon
the termination of the Operating Agreement for any reason.

 

F. The
Parties acknowledge that Company intends to convert from a Texas limited liability company to a Nevada corporation under the name Fresh
Vine Wine, Inc. (or such other jurisdiction or name determined by Company’s Board of Managers and approved by Company’s members
as required by applicable law) (the “Corporation”) in connection with a proposed initial public offering of the Corporation’s
common stock (the “IPO”). Such conversion is referred to herein as the “Conversion.” References
to the “Company” herein and in the Agreement shall refer to the Corporation following the Conversion. There is no assurance
that the Conversion or the IPO will occur.

 

G. Upon
the Conversion, Company will continue to exist without interruption in the organizational form of the Corporation (rather than as a limited
liability company) and the units representing Licensor’s outstanding membership interests in Company will convert into shares of
common stock of the Corporation, at which time Licensor will cease to be a Member of Company and will, instead, be a stockholder of the
Corporation. Also upon the Conversion, the Operating Agreement will be terminated and be of no further force or effect.

 

H. Section
20 of the STCs provides that the Agreement may be amended, modified or canceled only by a written agreement signed by the Parties thereto.

 

     

     

    

 

I. The
Parties desire to amend the Agreement pursuant to the Amendment so that the Agreement does not terminate at or following the Conversion
upon Licensor ceases to be a Member of Company or upon the termination of the Operating Agreement.

 

J. The
Parties further wish to amend the Agreement to accelerate the date on which Company is required to commence paying a license fee to Licensor
from the first anniversary of the Effective Date to the earlier of the first anniversary of the Effective Date or the initial closing
date of the IPO, and to provide the other rights set forth herein.

 

AGREEMENTS

 

NOW,
THEREFORE, in consideration of the premises herein set forth and for other good and valuable consideration, the nature, receipt and sufficiency
of which is hereby acknowledged, the Parties hereto hereby agree as follows:

 

1. Amendment
to Termination Provision. Section 15.2 of the STCs shall be amended in its entirety to read as follows:

 

“15.2
Licensor shall have the right to terminate this Agreement without prejudice to any other rights that Licensor may have, upon written
notice to Company: for (i) Cause; (ii) if Company materially breaches any material term, condition, obligation, representation or
warranty provided for in this Agreement and fails to cure such breach within thirty (30) days after Licensor has delivered a written
notice that includes a description of such breach and Licensor’s specifications for what would constitute a cure of such
breach (to the extent curable). Furthermore, if as of the end of calendar year 2023, Company has not achieved at least Five Million
Dollars ($5,000,000) in EBITDA in either Company’s 2022 fiscal year or Company’s 2023 fiscal year, then Licensor shall
have the right to terminate this Agreement, without prejudice to any other rights that Licensor may have, upon written notice to
Company to be received within thirty (30) following Company’s providing notice to Licensor of Company’s EBITDA for its
fiscal year 2023. Company shall calculate and provide notice to Licensor of Company’s EBITDA for each of its fiscal year 2022
and 2023 no later than March 31 of the following year.”

 

2. Compensation.
Notwithstanding Section 6(b) of the Basic Terms, the Parties hereby agree that Company shall commence paying the license fee of $300,000
per year on earlier of the first anniversary of the Effective Date or the initial closing date of the IPO.

 

3. Grossed-Up
Tax Indemnity. Company agrees to indemnify and reimburse Licensor for all United States federal and state income taxes that may become
due and payable by Licensor solely as a result of the assignment and transfer of the Restored Units by Nechio & Novak FV, LLC to
Licensor and Licensor’s receipt of this tax indemnity payment from Company. Prior to the filing of any tax return associated with
a claim for indemnification under this Section 3(b) (a “Tax Return”), Licensor shall provide to Company Licensor’s
calculation of the amount of income taxes for which Licensor is seeking indemnification and any supporting information reasonably requested
by Seller in connection therewith. Company shall satisfy Licensor’s claim for indemnification and reimburse Licensor for the indemnifiable
amounts no later than thirty (30) days following the filing the applicable Tax Return.

 

    2

     

    

 

4. Board
Observation Rights. During the term of the Agreement, Licensor shall be entitled to serve as a non-voting observer to Company’s
Board of Directors (in such capacity, Licensor is referred to herein as the “Observer”). Company will permit the Observer
to attend all meetings, excluding committee meetings and executive sessions of independent directors, of Company’s Board of Directors
(the “Board”) in a non-voting, observer capacity. The Observer may participate fully in discussions of all matters
brought to the Board for consideration, but in no event shall the Observer (i) be deemed to be a member of the Board; or (ii) except
for (and without limitation of) the obligations expressly set forth in this Agreement, have or be deemed to have, or otherwise be subject
to, any duties (fiduciary or otherwise) to Company or its stockholders. The presence of the Observer shall not be taken into account
or required for purposes of establishing a quorum. Upon request received from the Observer, Company shall give the Observer copies of
all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided
to such directors, and the Observer agrees to hold in confidence and trust all information so provided. Notwithstanding the foregoing,
that Company reserves the right to exclude the Observer from any Board meeting or portion thereof, and deny the Observer access to any
material provided to directors, if the Board in good faith determines that such exclusion is reasonably necessary (i) to preserve attorney-client
privilege or work product privilege, or (ii) to avoid a conflict of interest for or with Company.

 

5. Certain
Company Governance Rights. Under the Operating Agreement, Licensor has the right to designate one Manager (the “ND Designee”)
to serve on Company’s Board of Managers. The Operating Agreement further provides that Company may not take specified actions without
the affirmative vote or written consent of either the JH Designee or ND Designee, including without limitation Major Decisions made by
the Board (the “Special Approval Rights”). In addition, at any time during which an ND Designee is not serving as
a Manager, due to such person’s resignation or removal without the filling of the resulting vacancy or otherwise, the Special Approval
Rights of the ND Designee under the Operating Agreement are instead vested in Licensor in her capacity as a Class F Member of Company
or controlling affiliate of a Class F Member, and not as a Manager. Notwithstanding the fact that the Operating Agreement will be terminated
upon the Conversion, Company agrees that the Special Approval Rights shall continue to apply with respect to actions taken or proposed
to be taken by the Corporation after the Conversion in the same manner in which they applied to actions taken or proposed to be taken
by Company prior to the Conversion; provided; however, that the Special Approval Right shall terminate and have no further force or effect
upon the effective time of the registration statement registering the offer and sale of Company securities in the IPO. If, following
the Conversion, the closing of the IPO does not occur as a result of Company electing to abandon the offering or otherwise, upon the
request of either party, Company and Licensor will cooperate with each other in good faith to prepare and enter into a formal written
agreement reflecting Licensor’s continued Special Approval Rights.

 

6. Effective
Date of Amendment. This Amendment shall be effective as of the Amendment Date.

 

7. Representations.
Company and Licensor each represents and warrants that: (a) such Party has the power and legal right and authority or capacity, as applicable,
to enter into this Amendment and that this Amendment constitutes the legal, valid and binding obligation of such Party and is enforceable
against such Party in accordance with its terms.

 

8. Affirmation;
Entire Agreement. Except as expressly provided in this Amendment, no term of the Agreement shall be waived, amended or otherwise
modified as a result of the entry into this Amendment. The Agreement, as amended by this Amendment, sets forth the Parties’ final
and entire agreement with respect to the subject matter hereof and thereof and supersedes any and all prior understandings and agreements.

 

    3

     

    

 

9. Governing
Law, Remedies. This Amendment will be governed by and construed in accordance with the internal substantive laws of the State of
California, without giving effect to the principles of conflicts of laws thereof.

 

10.
Miscellaneous. The section headings in this Amendment are for convenience only and are not intended to be a complete or accurate
summary of the contents of any section. They shall not be used in construing this Agreement or any part hereof. The Agreement, as amended
by this Amendment, embodies the entire understanding of the Parties with respect to the subject matter contained in the Agreement and
this Amendment and supersedes all prior and contemporaneous agreements, representations, or understandings, written or oral, between
Licensor and Company. This Amendment may be executed in counterparts, each of which shall be deemed an original, and all of which together
shall constitute one and the same instrument.

 

Signature
Page Follows.

 

    4

     

    

 

IN
WITNESS WHEREOF, the Parties have duly accepted and agreed to this Amendment and agree to be bound hereby as of the dated first written
above.

 

	 	COMPANY:
	 	 
	 	FRESH GRAPES,
    LLC
	 	 
	 	By:	/s/ Damian Novak
	 	 	Damian Novak, Executive Chairman

 

 

	 	LICENSOR: 
	 	 
	 	/s/ Nina Dobrev
	 	Nina Dobrev

 

    5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}]]